Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-07-26, Stock:NVS, The news for the past five days is as follows:
2018-07-19: NEWS1: Novartis won’t raise drug prices in US.NEWS2: Novartis&apos; (NVS) Kisqali Gets FDA Nod for Label Expansion.NEWS3: Novartis Sues to Block Generic Sales of Top Drug Gilenya for MS.NEWS4: Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut.NEWS5: [$$] Novartis, MorphoSys and Galapagos Shares Rise on Drug Deal.NEWS6: The Swiss Stock Market Slipped Into The Red Going Into The Close.NEWS7: The Swiss Stock Market Slipped Into The Red Going Into The Close.NEWS8: European Markets Finished Mixed In Lackluster Trade.NEWS9: European Markets Finished Mixed In Lackluster Trade.NEWS10: Trump thanks Novartis, Pfizer for not raising drug prices.NEWS11: Novartis to Pay as Much as $1 Billion for Rights to Skin Drug.NEWS12: Novartis to pay 95 mln euros to Galapagos, MorphoSys for skin drug.NEWS13: European Shares Slide On Mixed Earnings.NEWS14: European Shares Slide On Mixed Earnings.NEWS15: Novartis Buys Exclusive Rights To IL-17C Compound MOR106 For Atopic Dermatitis.NEWS16: Novartis Buys Exclusive Rights To IL-17C Compound MOR106 For Atopic Dermatitis.NEWS17: [$$] Novartis Won’t Raise U.S. Drug Prices This Year.
2018-07-20: NEWS1: Pfizer gets FDA approval for drug similar to Amgen&apos;s Neupogen.NEWS2: Top Research Reports for Microsoft, Novartis & Goldman Sachs.NEWS3: Top Research Reports for Microsoft, Novartis & Goldman Sachs.NEWS4: Merck to Cut Price of Few Drugs Amid Drug Pricing Controversy.NEWS5: Merck to Cut Price of Few Drugs Amid Drug Pricing Controversy.NEWS6: Bullish Two Hundred Day Moving Average Cross - NVS.NEWS7: Bullish Two Hundred Day Moving Average Cross - NVS.NEWS8: Swiss, German drugmakers join U.S. price freeze.NEWS9: Top Research Reports for Microsoft, Novartis & Goldman Sachs.NEWS10: Swiss, German drugmakers join U.S. price freeze.NEWS11: Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals.NEWS12: Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals.NEWS13: Pharma Stock Roundup: JNJ & NVS&apos; Q2 Earnings, FDA Approvals.NEWS14: Swiss, German drugmakers join U.S. price freeze.NEWS15: The Swiss Stock Market Climbed Despite Trade Worries.NEWS16: The Swiss Stock Market Climbed Despite Trade Worries.NEWS17: Three Key Takeaways From Healthcare Earnings Season.NEWS18: Free Post Earnings Research Report: Novartis’ Net Sales Jumped 7%; Non-GAAP EPS Advanced 6%.NEWS19: Valsartan Drugs Recalled Over Potential Carcinogen Contamination.NEWS20: Valsartan Drugs Recalled Over Potential Carcinogen Contamination.NEWS21: Novartis' (NVS) Kisqali Gets FDA Nod for Label Expansion.NEWS22: Novartis' (NVS) Kisqali Gets FDA Nod for Label Expansion.NEWS23: Roche's Tecentriq Met Primary Goal in First-Line NSCLC Study.NEWS24: Roche's Tecentriq Met Primary Goal in First-Line NSCLC Study.
2018-07-23: NEWS1: What's in the Cards for Glaxo (GSK) This Earnings Season?.NEWS2: What's in the Cards for Glaxo (GSK) This Earnings Season?.NEWS3: What&apos;s in the Cards for Glaxo (GSK) This Earnings Season?.NEWS4: Amgen (AMGN) to Report Q2 Earnings: Will it Beat Again?.NEWS5: Amgen (AMGN) to Report Q2 Earnings: Will it Beat Again?.NEWS6: BIIB, LLY Q2 Earnings on Jul 24: Here are the Key Predictions.NEWS7: BIIB, LLY Q2 Earnings on Jul 24: Here are the Key Predictions.NEWS8: Novartis’s Innovative Medicines Segment in Q2 2018.NEWS9: Should GlaxoSmithKline Break Up?.NEWS10: Should GlaxoSmithKline Break Up?.NEWS11: Tilray’s IPO Looks Badly Overpriced – And It Might Not Matter.NEWS12: The Zacks Analyst Blog Highlights: Microsoft, Novartis, Goldman Sachs, Starbucks and General Motors.NEWS13: The Zacks Analyst Blog Highlights: Microsoft, Novartis, Goldman Sachs, Starbucks and General Motors.NEWS14: Novartis in Q2 2018: Segment Performances.NEWS15: Should GlaxoSmithKline Break Up?.NEWS16: The Zacks Analyst Blog Highlights: Microsoft, Novartis, Goldman Sachs, Starbucks and General Motors.NEWS17: Novartis’s Q2 2018 Revenue Growth.NEWS18: The Swiss Stock Market Dropped At The Start Of The Trading Week.NEWS19: The Swiss Stock Market Dropped At The Start Of The Trading Week.
2018-07-24: NEWS1: Biogen Stock Trending Higher on Strong Q2 2018 Results.NEWS2: Lilly (LLY) Tops Q2 Earnings, Chooses IPO Path for Elanco.NEWS3: Lilly (LLY) Tops Q2 Earnings, Chooses IPO Path for Elanco.NEWS4: Novartis's Cultural Revolution Will Be AI-Enabled and Desk-Free.NEWS5: Novartis’s Key Developments in July.NEWS6: Novartis’s Q2 2018 Earnings: Alcon.NEWS7: The Swiss Stock Market Climbed On Bank Strength.NEWS8: The Swiss Stock Market Climbed On Bank Strength.NEWS9: Novartis’s Q2 2018 Earnings: Sandoz.NEWS10: J&J’s Oncology Franchise Saw 42.2% Growth in Q2 2018.
2018-07-25: NEWS1: Why AnaptysBio Rose 10.5% Today.NEWS2: Why AnaptysBio Rose 10.5% Today.NEWS3: Why AnaptysBio Rose 10.5% Today.NEWS4: Gilead's Earnings Fail to Impress.NEWS5: Glaxo (GSK) Beats on both Earnings and Revenue in Q2.NEWS6: Did This Top Biotech Stock Just Go on Sale?.NEWS7: Did This Top Biotech Stock Just Go on Sale?.NEWS8: The Swiss Stock Market Rose Slightly On Roche Strength.NEWS9: The Swiss Stock Market Rose Slightly On Roche Strength.NEWS10: Novartis’s Valuation after Its Q2 2018 Earnings.

Answer: Rise